Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) FCF Margin: 2021-2025

Historic FCF Margin for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Sep 2025 value amounting to -51.90%.

  • Rhythm Pharmaceuticals' FCF Margin rose 2394.00% to -51.90% in Q3 2025 from the same period last year, while for Sep 2025 it was -62.60%, marking a year-over-year increase of 4796.00%. This contributed to the annual value of -87.51% for FY2024, which is 8840.00% up from last year.
  • Rhythm Pharmaceuticals' FCF Margin amounted to -51.90% in Q3 2025, which was down 7.97% from -48.07% recorded in Q2 2025.
  • Rhythm Pharmaceuticals' FCF Margin's 5-year high stood at -45.05% during Q4 2024, with a 5-year trough of -95,837.14% in Q1 2021.
  • In the last 3 years, Rhythm Pharmaceuticals' FCF Margin had a median value of -121.24% in 2023 and averaged -125.84%.
  • Data for Rhythm Pharmaceuticals' FCF Margin shows a peak YoY soared of 9,224,842bps (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Rhythm Pharmaceuticals' FCF Margin stood at -2,231.15% in 2021, then soared by 184,436bps to -386.79% in 2022, then soared by 26,555bps to -121.24% in 2023, then soared by 7,619bps to -45.05% in 2024, then spiked by 2,394bps to -51.90% in 2025.
  • Its last three reported values are -51.90% in Q3 2025, -48.07% for Q2 2025, and -123.38% during Q1 2025.